Results for tag: "Secondary Hyperparathyroidism Drug"

Secondary Hyperparathyroidism (SHPT) is a condition caused by chronic kidney disease (CKD) in which the parathyroid glands produce too much parathyroid hormone (PTH). This can lead to an imbalance of calcium and phosphorus in the body, resulting in bone and mineral disorders. Treatment for SHPT typically involves medications that reduce the production of PTH, such as cinacalcet, vitamin D analogs, and calcimimetics. These drugs are part of the Endocrine and Metabolic Disorders Drugs market, which also includes drugs for diabetes, obesity, and thyroid disorders. The SHPT drug market is growing due to the increasing prevalence of CKD and the need for effective treatments. The market is expected to benefit from the development of new drugs and the increasing availability of generic drugs. Companies in the SHPT drug market include Amgen, AbbVie, Novartis, Merck, and Pfizer. Show Less Read more